elive™ Platform Validation
Multiple Solid Tumors (NSCLC, Bladder, Colorectal, etc.)
Key Facts
About Elephas Biosciences
Elephas Biosciences is pioneering a novel functional diagnostics platform designed to predict immunotherapy response using live tumor tissue. Its core technology, elive™, preserves the native tumor microenvironment and measures dynamic cytokine activity ex vivo to provide a more biologically relevant prediction of therapeutic efficacy than static biomarkers. The company is currently validating its platform through multiple observational clinical trials while engaging with pharmaceutical R&D, research scientists, and medical oncologists through partnership and early access models. Elephas operates as a private, pre-revenue company focused on establishing the clinical utility of its diagnostic approach.
View full company profile